Atlas, J&J venture arm back newco Rodin
Epigenetics company Rodin Therapeutics Inc. (Cambridge, Mass.) debuted on Thursday with undisclosed seed funding from Atlas Venture and Johnson & Johnson Development Corp. (JJDC), the venture arm of Johnson & Johnson (NYSE:JNJ). The seed funding is tied to a committed, tranched series A round.
Rodin is developing epigenetic small molecule modulators to treat CNS disorders, including Alzheimer's disease (AD). Founding shareholder Proteros biostructures GmbH (Martinsried, Germany) granted Rodin exclusive rights to its services for a set of undisclosed targets and access to Proteros' structural biology platform. Proteros also is helping to advance Rodin's pipeline by performing early drug discovery work around screening, profiling and early chemical optimization. ...